Shares of Tharimmune, Inc. (THAR) jumped 207% on Wednesday as the biotechnology company announced positive simulation results of its lead clinical candidate, TH104. THAR stock gained another 42% in after-hours trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
What Does Tharimmune Do?
Tharimmune is a clinical-stage biotech firm focused on developing treatments for inflammatory and immune-related conditions. Its lead candidate, TH104, currently in clinical trials, is an experimental drug being developed to prevent the effects of fentanyl and other strong opioids.
Tharimmune is studying how TH104 behaves in the body using a pharmacokinetic (PK) simulation. TH104 is a thin film placed in the mouth (buccal film) that delivers nalmefene, a medicine being tested for its effects.
For context, pharmacokinetic simulation is a way scientists predict how a drug moves through the body. It checks how it’s absorbed, distributed, broken down, and eliminated, without testing it fully in people yet.
What TH104’s Results Mean for Tharimmune
The latest results suggest that TH104 could help prevent the effects of fentanyl and other strong opioids. It may start working within 30 minutes and provide protection for about 24 hours. This gives TH104 a major advantage over current treatments like naloxone, which usually works for only 30–90 minutes.
Additionally, the results highlight TH104’s potential as a preventive treatment for military personnel and first responders who might be exposed to powerful opioids, including weaponized fentanyl. Notably, fentanyl and similar drugs are a national security concern because of their extreme potency and the risk of mass casualties if used as weapons. Therefore, there is an urgent need for treatments that can be given in advance to protect people and prevent the rapid effects on breathing and the nervous system caused by these drugs.
What’s Happening with THAR Stock?
Tharimmune’s stock has traded between $0.95 and $6.39 over the past 52 weeks. Year-to-date, THAR stock is up by 77%.
Over a longer time frame of 5 years, THAR stock has declined by almost 100%.
